IQVIA Sees Demand Growth as Bookings and Guidance Expand

IQVIA Holdings Inc. entered the final quarter of 2026 with expanding backlogs and raised annual financial guidance following a third-quarter performance that exceeded previous forecasts. On its earnings call, management cited accelerating revenue growth and expanding profit margins, which were bolstered by a funding recovery among emerging biopharma companies. Net new bookings for clinical research over the trailing twelve months reached $11.7 billion, representing an increase of 14% year over year.

Executive Vice President and Chief Financial Officer Michael J. Fedock noted that the trailing twelve-month booking figure has climbed steadily across each of the past five quarters. While pass-through expenses from third-party vendor services created a headwind of roughly 70 basis points on the gross margin line, Fedock indicated that internal workflow automation helped offset non-operational costs to keep margins expanding. Chairman and Chief Executive Officer Ari Bousbib highlighted that year-over-year organic growth accelerated twice as fast for commercial analytics and nearly three times as fast for clinical research.

Bousbib also pointed to client adoption of artificial intelligence software within commercial client organizations, noting that deeper trust has prompted customers to deploy more of the company's automated tools. These software tools help pharmaceutical and biotech customers shorten trial timelines and analyze complex medical data. The operational execution across research and development supported management's decision to lift full-year 2026 revenue expectations to a range of US$17.35b to US$17.5b, along with higher targets for Adjusted EBITDA and adjusted diluted earnings per share.

In recent trading, shares of IQVIA closed at USD 271.83, marking a 2.62% increase on trading volume of 1.4M shares. That valuation places the company's market capitalization at USD 44.8B. Over the trailing twelve months, diluted earnings per share totaled USD 8.23, an increase of 12.98% compared to the prior-year period. The shares trade at a price-to-earnings ratio of 33.03 and carry a dividend yield of 0.00%.